Kietpeerakool Chumnan, Srisomboon Jatupol
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Int J Clin Oncol. 2009 Feb;14(1):37-42. doi: 10.1007/s10147-008-0795-x. Epub 2009 Feb 20.
Cervical intraepithelial neoplasia (CIN) II, III is a preinvasive stage of squamous cell carcinoma of the uterine cervix. The standard treatment for CIN II, III consists of ablation and excision. However, nonsurgical treatment may be necessary for some women to preserve future reproductive potential. This review was conducted to summarize available published data on the efficacy and safety of medical treatment for CIN II, III. Based on existing studies, cyclooxygenase (COX)-2 inhibitors; indole-3-carbinol; and novel immunotherapy agents, including ZYC101a, MVA E2, and HspE7, have been observed as possessing therapeutic activity without any major treatment-related complications. These promising results provide important data for the future direction of clinical research.
宫颈上皮内瘤变(CIN)II、III级是子宫颈鳞状细胞癌的癌前阶段。CIN II、III级的标准治疗包括消融和切除。然而,对于一些女性来说,为保留未来的生殖潜能,可能需要非手术治疗。本综述旨在总结已发表的关于CIN II、III级药物治疗疗效和安全性的可用数据。基于现有研究,已观察到环氧合酶(COX)-2抑制剂、吲哚-3-甲醇以及新型免疫治疗药物(包括ZYC101a、MVA E2和HspE7)具有治疗活性,且无任何与治疗相关的严重并发症。这些有前景的结果为临床研究的未来方向提供了重要数据。